Fat-Loss Peptides UK: An Evidence-Ranked Guide

Not every "fat-loss peptide" has the same quality of evidence behind it. This guide ranks the field honestly, from the compound with approved fat-outcome data down to the ones that never left mouse models.

Fat loss is the most commercially crowded corner of the UK peptide market and the one where evidence quality varies most wildly between compounds that sit on the same shelf. Some of the compounds below have randomised human trial data; others have mouse data and marketing. This guide sorts them by what the evidence actually shows, explains the different mechanisms, and sets out the UK legal position. Nothing here is medical advice — all compounds are supplied for research purposes only and are not for human or veterinary use.

The central problem: "fat-loss peptide" is not one category

The phrase lumps together at least three genuinely different things. The incretin class (semaglutide, tirzepatide, retatrutide, mazdutide) reduces body weight primarily by suppressing appetite and slowing gastric emptying — the fat loss is downstream of eating less. The growth-hormone pathway compounds (tesamorelin, AOD-9604, CJC-1295 + ipamorelin) aim at fat tissue more directly, through lipolysis and visceral-fat targets. And the mitochondrial and metabolic research peptides (MOTS-c) examine energy utilisation in laboratory models.

Treating these as interchangeable is the first mistake buyers make. They have different mechanisms, different evidence grades and different risk profiles, and a page that presents them as a menu of equivalent "fat burners" is telling you something about the seller, not the science.

Tesamorelin: the strongest evidence in the category

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue. It stimulates the pituitary to release the body's own growth hormone in a pulsatile pattern, and it is the one compound in this space with an approved indication for a fat outcome — reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

The evidence is unusually deep for a peptide. Multiple randomised Phase 3 trials demonstrated statistically significant reductions in visceral adipose tissue versus placebo, with response typically defined as a ≥8% reduction in visceral fat, achieved by roughly 70% of treated participants. A 2026 meta-analysis of randomised controlled trials reported a mean visceral adipose tissue reduction of around 28 cm², alongside reductions in trunk fat, limb fat and hepatic fat percentage, with a more favourable safety profile than exogenous growth hormone.

Two honest caveats. First, the foundational trials were in HIV-positive populations with abdominal fat accumulation — a specific group, not the general public. Second, the mechanism raises IGF-1 and affects glucose metrics, which is exactly why such research runs under clinical monitoring. The compound is not licensed in the UK; as sold here it is research material only.

AOD-9604: the cautionary tale

AOD-9604 is a modified fragment of human growth hormone (residues 176-191), developed specifically to isolate the fat-metabolising portion without the growth-promoting effects. The mechanism story is elegant, and its preclinical data is genuinely interesting — obese-mouse studies showed increased fat oxidation and weight loss.

The human data is where the story changes. AOD-9604 progressed to a Phase 2b human obesity trial that did not meet its primary weight-loss endpoint versus placebo. The mouse effect was not reproduced in humans at the studied dose. This is not a fringe reading — it is the standard description of the compound's clinical history in the research literature, and any page claiming otherwise is selling rather than reporting.

AOD-9604 remains a legitimate research compound with a well-defined mechanism and a clear COA story. What it does not have is human efficacy data. Those are different things, and the gap between them is the whole lesson of this category.

MOTS-c and the metabolic-research tier

MOTS-c is a mitochondrial-derived peptide studied in glucose metabolism, insulin sensitivity and energy-utilisation research. It sits in a genuinely interesting scientific space — mitochondrial signalling is one of the more active research frontiers — but its fat-loss evidence is laboratory and model-based, not human outcome data. It belongs in the research tier, described as mechanism and direction rather than demonstrated fat loss.

The same honesty applies to the wider growth-hormone stack space. CJC-1295 with ipamorelin is studied for pulsatile growth-hormone release, and fat metabolism is a plausible downstream consequence of that pathway. "Plausible downstream consequence" is not the same as "proven fat-loss outcome", and the distinction should survive the journey from the research paper to your shortlist.

The incretin class: the strongest weight data, different mechanism

If the question is weight loss rather than fat tissue, the strongest human data in the entire field belongs to the incretin class. Semaglutide and Tirzepatide are licensed medicines in the UK; the MHRA approved an oral semaglutide (Wegovy) tablet for weight loss in June 2026, the first oral GLP-1 authorised for the indication. Retatrutide, the triple agonist, reported in the Phase 3 TRIUMPH-1 trial (2026) an average 28.3% weight loss at 80 weeks at the 12 mg dose — but remains investigational. Mazdutide and cagrilintide + semaglutide sit at the newer end of the same class.

The mechanics matter for interpreting the numbers: these compounds cause weight loss largely by reducing intake. Their side-effect profile — gastrointestinal events, dose escalation effects, in retatrutide's case a dysesthesia signal — is covered in the retatrutide side effects guide.

What the evidence supports, and where it stops

• Strongest human fat-outcome data: tesamorelin for visceral fat, in defined populations
• Strongest overall weight-loss data: the incretin class — but via appetite, not direct fat targeting
• Mechanistic only: MOTS-c, and the GH-stack compounds' fat-loss claims
• Failed its human endpoint: AOD-9604, despite compelling mouse data

Two myths worth discarding. First, "it works in mice, so it works" — AOD-9604 is the standing counterexample in this exact category. Second, "the strongest weight loss must be the best fat-loss compound" — appetite suppression and visceral-fat targeting are different jobs, and the compound that wins one is not automatically the compound that wins the other. What matters operationally, as always, is documentation: HPLC purity, a per-batch certificate of analysis, mass-spectrometry identity, and cold-chain handling from a UK warehouse.

Is it legal in the UK?

None of these compounds is a controlled substance under the Misuse of Drugs Act 1971. The MHRA treats peptides sold for human use as unlicensed medicines and directs enforcement at sellers and suppliers rather than individual importers; personal importation is a grey zone tolerated in practice rather than explicitly legal. The "research purposes only" label is a real but soft shield — the MHRA has indicated it may disregard the label where it is used to evade medicines regulation, and it treats the GLP-1 class as the highest-risk "research" category, with active enforcement through 2026. Buying UK-held stock removes import exposure, including the 20% import VAT and the £135 declaration threshold applied to incoming international orders.

Where this fits at Peptide Supply Guy

The fat-loss and metabolism range is stocked in the UK with a certificate of analysis available per batch, strictly for research purposes:

• Tesamorelin — from £18.70 per vial (card price)
• AOD-9604 — from £17.85 per vial (card price) · full page: what it is, where it sits, supply and ordering
• MOTS-c — from £12.75 per vial (card price)
• Retatrutide, tirzepatide, semaglutide, mazdutide — the incretin range
• CJC-1295 + ipamorelin — the GH-pairing option

For the research question of visceral fat specifically, tesamorelin is the compound with the documented evidence base. For the weight-loss question, the incretin class is where the human data lives. All compounds are supplied strictly for research purposes only, with no dosing or medical guidance provided.

On-page frequently asked questions